Ziprasidone decreases cortisol excretion in healthy subjects (Q30498400)

16 October 2017

Ziprasidone decreases cortisol excretion in healthy subjects (English)

1 reference

16 October 2017

0 references

Andreas Meier

1

1 reference

16 October 2017

Anna-Catharina Neumann

2

1 reference

16 October 2017

Wolfgang Jordan

3

1 reference

16 October 2017

Gerald Huether

4

1 reference

16 October 2017

Andrea Rodenbeck

5

1 reference

16 October 2017

Eckart Rüther

6

1 reference

16 October 2017

Stefan Cohrs

7

1 reference

16 October 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

British Journal of Clinical Pharmacology

16 October 2017

1 reference

16 October 2017

60

1 reference

16 October 2017

3

1 reference

16 October 2017

330-336

1 reference

Stress and the genesis of diabetes mellitus in schizophrenia

16 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Invited review: the evolution of antidepressant mechanisms

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Association of depression with medical illness: does cortisol play a role?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Pharmacological profile of neuroleptics at human monoamine transporters

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Platelet 5-HT and plasma cortisol concentrations after dexamethasone suppression test in patients with different time course of schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Effects of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desimipramine-induced pituitary hormone stimulation in humans--III. Hypothalamo-pituitary-adrenocortical axis.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Positive and negative symptoms in schizophrenia and the Dexamethasone Suppression Test.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

The influence of psychotropic drugs and releasing hormones on anterior pituitary hormone secretion in healthy subjects and depressed patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

20 June 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02431.X

Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02431.X

Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02431.X

The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02431.X

Role of 5-HT in the regulation of the brain-pituitary-adrenal axis: effects of 5-HT on adrenocortical cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02431.X

Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02431.X

Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02431.X

Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02431.X

Sleep-promoting properties of quetiapine in healthy subjects

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Serotonergic regulation of cortisol secretion in dogs.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884774

Ritanserin, a Serotonin-S 2 Receptor Antagonist, Does Not Prevent 5-Hydroxytryptophan-Induced β-EP, β-LPH and Cortisol Secretion

26 November 2018

1 reference

12 December 2020

Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine

1 reference

12 December 2020

Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine

1 reference

12 December 2020

Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers

1 reference

12 December 2020

Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II

1 reference

12 December 2020

No evidence for a physiological coupling between melatonin and glucocorticoids

1 reference

12 December 2020

Switch from neuroleptics to clozapine does not influence pituitary–gonadal axis hormone levels in male schizophrenic patients

1 reference

12 December 2020

10.1111/J.1365-2125.2005.02431.X

Identifiers

DOI

1 reference

16 October 2017

1 reference

16 October 2017

1 reference